We are seeking participants with type 2 diabetes who use insulin and whose diabetes has affected kidney function and are interested in trying out a new medication that is expected to improve blood sugar control and prevent the weight gain (or induce weight loss) associated with increased insulin use. Compensation for time and travel are provided.

The purpose of this study is to compare diet (record of the foods you eat), gut microbiome (stool sample), and cells (blood sample) in adults with IgA Nephropathy (IgAN) and compare with adults with focal segmental glomerulosclerosis (FSGS) and adults with no history of medical problems. The information we learn by doing this study may help us understand how we might be able to target the microbiome to better understand the disease process and potentially help us develop new therapies in the future.

Primary Objective: Demonstrate the superiority of belumosudil in combination with prednisone vs placebo in combination with prednisone in Event-Free Survival (EFS) Secondary Objective:Demonstrate the superiority of belumosudil in combination with prednisone vs placebo incombination with prednisone in modified Lee Symptom Scale (mLSS) improvement,overall ,response rate (ORR) and in the rate of corticosteroid withdrawal

Do you have Type 1 Diabetes and Chronic Kidney Disease as a result of your diabetes? Do you want stop or slow the progression of your kidney disease? If so, you may be able to take part in the FINE-ONE study to learn more about a kidney drug called finerenone. Compensation is provided for participation.

Cyclophosphamide is a chemotherapy (chemo) drug often given after a transplant to prevent GvHD. We are doing this study to see if a lower dose of cyclophosphamide after transplant is safer, but just as effective. Cyclophosphamide can prevent GvHD, but it can also make you sick and more likely to get an infection. This study will look at how well a lower dose of cyclophosphamide works to reduce these side effects, while also preventing GvHD. This study does not include any new or untested drugs. The drugs and procedures in this study are standard for transplant.

The study treatment, finerenone, is being developed to help people who have long lasting kidney disease, also known as chronic kidney disease (CKD). It works by blocking a certain hormone called aldosterone that causes injury and inflammation in the heart and kidney which is known to play a role in CKD. In this study, the researchers want to learn if finerenone works the same way in kidney transplant recipients. Some subjects will receive the study drug and some will receive a placebo.

Have you ever wondered what environmental toxins you are exposed to on a daily basis, and how it might affect your health? The STRIVE study is looking for volunteers who would like to provide blood, urine, and/or saliva, as well as home samples such as soil, dust, and/or water. In this study, we want to learn more about the environmental factors that contribute to advanced liver disease and liver cancer. We are looking for healthy volunteers and people with liver cirrhosis who live in either North Carolina or Georgia to take part.

We would like to learn about how people who apply for healthcare financial assistance experience the application process, including things that make the application process work well or that were challenging. At this time we are not able to offer interviews to people who applied to UNC or Duke, we are interested in hearing from people who applied to other programs (such as Atrium, Novant, Wake, Vidant, ECU, Cape Fear Health Net, Physicians Reach Out, or Project Access).

Are you overweight or obese? If you also have heart disease or kidney disease with at least two risk factors for carviovascular disease, you might be eligible to take part in a research study that may help you reach up to 19% weight loss. In this study, we want to learn if a drug that is being tested is effective in reducing heart disease risks and will help you reach a healthier weight and active lifestyle.

Post-transplant lymphoproliferative disorder (PTLD) is the name for types of lymphoma that sometimes develop in people who have had a transplant. It can affect people who are taking medicines to suppress their immune system. This study is being done to study whether treating PTLD with a combination of the drugs tafasitamab and rituximab is more effective than rituximab alone - the current standard of care treatment for this disease.